{
    "nctId": "NCT00004205",
    "briefTitle": "Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer",
    "officialTitle": "A Phase III Study to Evaluate Letrozole as Adjuvant Endocrine Therapy for Postmenopausal Women With Receptor (ER and/or PgR) Positive Tumors",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 8028,
    "primaryOutcomeMeasure": "Disease free survival.",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed resectable adenocarcinoma of the breast\n\n  * pT1, pT2, pT3, or minimal dermal involvement on pathology only\n  * pN0, pN1, pN2, or M0\n\n    * Negative nodal status\n\n      * At least 8 nodes are negative\n    * Unknown nodal status\n\n      * Less than 8 nodes examined and no pathological finding\n    * Positive nodal status\n\n      * Any positive finding independent of the number of nodes examined\n  * Negative sentinel node or no prior nodal dissection allowed if all other criteria met\n* Must have had total mastectomy, lumpectomy, or quadrantectomy\n\n  * Should have prior chest wall radiotherapy after segmental mastectomy or histopathologic T4 dermal involvement\n* Stage I, II, or IIIa allowed if the tumor is completely removed macroscopically and margins of the resected tumor are microscopically free of tumor\n* Must undergo chest wall radiotherapy or second resection if microscopic disease at the mastectomy margins\n* No bilateral disease except in situ disease, either ductal or lobular of the contralateral breast\n* Postmenopausal\n\n  * Regardless of prior hormonal replacement therapy (HRT) or hysterectomy:\n\n    * Bilateral oophorectomy and any age\n    * Radiologic castration and amenorrheic for at least 3 months and any age\n    * Not postmenopausal at the start of adjuvant chemotherapy AND and completed at least 6 courses of prior cyclophosphamide, methotrexate, and fluorouracil (CMF) or at least 4 courses of prior anthracycline-cyclophosphamide continuation therapy and at least age 45 with follicle stimulating hormone (FSH), luteinizing hormone (LH), and estradiol (E2) postmenopausal levels\n  * No prior HRT:\n\n    * Prior hysterectomy and less than age 55 with FSH/LH/E2 postmenopausal levels\n    * Prior hysterectomy and at least age 55\n  * No prior HRT or hysterectomy:\n\n    * Amenorrhea more than 1 year and less than age 50\n    * Amenorrhea more than 6 months and at least age 50\n  * Prior HRT regardless of hysterectomy:\n\n    * At least 1 month since prior HRT and less than age 55 with FSH/LH/E2 postmenopausal levels\n    * At least 1 month since prior HRT and at least age 55\n  * FSH/LH/E2 postmenopausal levels and uncategorized\n* No distant metastases, including bone scans showing hot spots unconfirmed as benign disease or skeletal pain of unknown cause\n* At least 10% hormone receptor-positive tumor cells\n* Hormone receptor status:\n\n  * Estrogen receptor positive AND/OR\n  * Progesterone receptor positive\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n* 30 and over\n\nSex:\n\n* Female\n\nMenopausal status:\n\n* Postmenopausal\n\nPerformance status:\n\n* Not specified\n\nLife expectancy:\n\n* Not specified\n\nHematopoietic:\n\n* WBC greater than 3,000/mm\\^3\n* Platelet count at least 100,000/mm\\^3\n* Hemoglobin greater than 10 g/dL\n\nHepatic:\n\n* Bilirubin less than 3.0 mg/dL\n* SGOT or SGPT less than 1.5 times upper limit of normal\n* No hepatic disease that would preclude study\n\nRenal:\n\n* Creatinine less than 1.8 mg/dL\n* No renal disease that would preclude study\n\nCardiovascular:\n\n* No cardiovascular disease that would preclude study\n* Prior deep vein thrombosis allowed if medically stable\n\nPulmonary:\n\n* No lung embolism\n\nOther:\n\n* No other prior or concurrent malignancy within the past 5 years except adequately treated basal or squamous cell skin cancer or carcinoma in situ of the cervix\n* No prior noncompliance to medical regimens\n* No other nonmalignant systemic diseases that would preclude follow-up\n* HIV negative\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy:\n\n* Prior immunotherapy or biological response modifiers (e.g., interferon) allowed\n\nChemotherapy:\n\n* See Disease Characteristics\n* Prior adjuvant or neoadjuvant chemotherapy allowed\n* Concurrent adjuvant chemotherapy allowed\n\nEndocrine therapy:\n\n* See Disease Characteristics\n* Prior neoadjuvant hormonal therapy allowed (e.g., antiestrogens, progestins, or aromatase inhibitors) if no more than 4 months duration and no disease progression\n* Prior corticosteroids allowed\n* At least 4 weeks since prior HRT\n* Prior adjuvant antiestrogen therapy allowed if less than 1 month duration and immediately after surgery, radiotherapy, and/or chemotherapy\n* Prior antiestrogens for chemoprevention allowed if at least 18 months between completion of chemoprevention and diagnosis\n* No other concurrent antiestrogens or aromatase inhibitors\n* No concurrent raloxifene\n* No concurrent systemic HRT with or without progestins of more than 3 months duration\n\nRadiotherapy:\n\n* See Disease Characteristics\n* Concurrent radiotherapy allowed\n\nSurgery:\n\n* See Disease Characteristics\n\nOther:\n\n* At least 30 days since prior systemic investigational drugs\n* At least 7 days since prior topical investigational drugs\n* Concurrent bisphosphonates allowed",
    "sex": "FEMALE",
    "minimumAge": "30 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}